Search

Your search keyword '"Shen YN"' showing total 2 results
Start Over Author "Shen YN" Journal cancer letters
2 results on '"Shen YN"'

1. Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population.

Author

Li X, Ma T, Zhang Q, Chen YG, Guo CX, Shen YN, Sun PW, Li GG, Gao SL, Que RS, Lou JY, Yu RS, Yuan Y, Wei QC, Wei SM, Zhang Y, Zheng L, Bai XL, and Liang TB

Subjects
Adult, Aged, Camptothecin adverse effects, China epidemiology, Female, Humans, Irinotecan, Liver Neoplasms drug therapy, Liver Neoplasms epidemiology, Liver Neoplasms secondary, Lung Neoplasms drug therapy, Lung Neoplasms epidemiology, Lung Neoplasms secondary, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Oxaliplatin, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms pathology, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms epidemiology, Peritoneal Neoplasms secondary, Prognosis, Prospective Studies, Survival Rate, Antineoplastic Combined Chemotherapy Protocols adverse effects, Camptothecin analogs & derivatives, Neoplasm Metastasis drug therapy, Organoplatinum Compounds adverse effects, Pancreatic Neoplasms drug therapy
Abstract

FOLFIRINOX chemotherapy has shown remarkable responses in patients with metastatic pancreatic cancer (MPC), and has significantly improved prognosis. However, FOLFIRINOX is currently not frequently applied in China because of its high incidence of adverse events, and there is no recognized optimization for this therapy in Chinese population. Modification of FOLFIRINOX may be better for its acceptance in China. In this study, we evaluated the efficacy and safety of modified-FOLFIRINOX in patients with MPC. A total of 62 MPC patients were treated with modified-FOLFIRINOX (no Fluorouracil bolus, 85% Oxaliplatin and 75% Irinotecan) between April 2014 and April 2017 in our institute. 40 of them were evaluated, with a response rate of 32.5% (13/40). The frequent grade 3/4 adverse events are neutropenia (29%) and alanine aminotransferase elevation (14.5%). No treatment-related death was observed. The median overall survival and median progression-free survival are 10.3 months and 7.0 months, respectively. In conclusion, modified-FOLFIRINOX had significantly improved tolerance with similar efficacy to FOLFIRINOX. These findings may provide evidence for the use of FOLFIRINOX in Chinese patients with MPC., (Copyright © 2017. Published by Elsevier B.V.)

Published
2017
Full Text
View/download PDF

2. RRM1 maintains centrosomal integrity via CHK1 and CDK1 signaling during replication stress.

Author

Kim SH, Park ER, Joo HY, Shen YN, Hong SH, Kim CH, Singh R, Lee KH, and Shin HJ

Subjects
CDC2 Protein Kinase genetics, Cell Line, Tumor, Centrosome metabolism, Checkpoint Kinase 1, Cyclin A metabolism, Cyclin B metabolism, DNA Damage, DNA Replication genetics, Gene Knockdown Techniques, HeLa Cells, Humans, Protein Kinases genetics, RNA, Small Interfering administration & dosage, RNA, Small Interfering genetics, Ribonucleoside Diphosphate Reductase, Signal Transduction, Transfection, Tumor Suppressor Proteins deficiency, Tumor Suppressor Proteins metabolism, CDC2 Protein Kinase metabolism, Centrosome physiology, DNA Replication physiology, Protein Kinases metabolism, Tumor Suppressor Proteins genetics
Abstract

DNA lesion-induced centrosomal abnormalities during the replication phase are relatively unknown. Here, we report that RNAi-mediated depletion of RRM1 induces cell-cycle arrest at the replication phase, along with severe DNA damage and centrosomal amplification. Interestingly, CHK1 depletion synergistically increased RRM1-depletion-induced centrosomal amplification. In response to hydroxyurea, CHK1 was delocalized from the centrosome by RRM1 depletion. Moreover, CDK1, which functions in centrosome separation and is inhibited by CHK1, was found to be essential for RRMI1-depletion-induced centrosomal amplification. Thus, we herein demonstrate that RRM1 preserves chromosomal stability via the CHK1- and CDK1-dependent stabilization of the centrosomal integrity at the replication stage., (Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.)

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results